MASS SPECTROMETRY OF DRUGS, NATURAL PRODUCTS, PROTEINS, AND OLIGONUCLEOTIDES

药物、天然产物、蛋白质和寡核苷酸的质谱分析

基本信息

项目摘要

Research of the unit is split between the identification of biologically active trace organic compounds isolated from natural sources and the mass spectrometry of biopolymers (e.g. peptide, proteins and oligonucleotides). A very close working relationship and collaboration is maintained with the Laboratory of Biophysical Chemistry, NHLBI. While this group runs many routine analyses for laboratories at NIH, as much emphasis as possible is placed on research using mass spectrometry for the structural elucidation of biologically active compounds. This years key projects include: the structural identification of potent anti-HIV and anti-cancer compounds; the identification of post-translational modifications in proteins; continued research on cyanovirin, a potent anti-HIV compound heading towards clinical trial; development of techniques for micro- scale LCMS of biopolymers with the aim of greatly enhancing sensitivity; the identification and chiral determination of abnormal and modified amino acids as found in marine natural products; the identification of modified hemoglobins formed during treatments for sickle cell. Work has expanded into large proteins with multiple glycosylation sites and many overlapping disulfides. Multiple enzymatic digestion protocols and sophisticated software have been developed to solve these problems. A collaboration continues with The National Institute of Standards and Technology (NIST) involving the measurement of mass spectra of organic compounds from NIH, the Walter Reed Army Institute of Research and other government agencies. These are then put into the NIST/EPA/NIH mass spectral database which is in use world wide. - mass spectrometry, proteins, disulfides, glycosylation, electrospray, natural products, anti-HIV, sickle cell anemia
该单位的研究分为从天然来源分离的生物活性微量有机化合物的鉴定和生物聚合物(如肽,蛋白质和寡核苷酸)的质谱分析。与NHLBI生物物理化学实验室保持着非常密切的工作关系和合作。虽然这个小组为NIH的实验室进行了许多常规分析,但尽可能多地强调使用质谱法研究生物活性化合物的结构。今年的重点项目包括:强效抗艾滋病和抗癌化合物的结构鉴定;蛋白质翻译后修饰的鉴定;继续研究强效抗艾滋病毒化合物氰维林(cyanovirin),该药物即将进入临床试验阶段;发展生物聚合物的微尺度LCMS技术,以期大大提高灵敏度;海洋天然产物中异常氨基酸和修饰氨基酸的鉴定及手性测定镰状细胞治疗过程中形成的修饰血红蛋白的鉴定。工作已经扩展到具有多个糖基化位点和许多重叠二硫化物的大型蛋白质。多种酶消化方案和复杂的软件已经开发出来解决这些问题。与美国国家标准与技术研究所(NIST)的合作仍在继续,涉及来自美国国立卫生研究院、沃尔特里德陆军研究所和其他政府机构的有机化合物的质谱测量。然后将这些数据输入NIST/EPA/NIH的质谱数据库,该数据库在世界范围内使用。-质谱,蛋白质,二硫化物,糖基化,电喷雾,天然产物,抗hiv,镰状细胞性贫血

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Lewis K. Pannell其他文献

Cobalt(II) complexes of the 2-aminopicolineN-oxides and 2-amino-4, 6-lutidineN-oxide
  • DOI:
    10.1007/bf01041498
  • 发表时间:
    1988-02-01
  • 期刊:
  • 影响因子:
    1.700
  • 作者:
    Douglas X. West;John C. Severns;Lewis K. Pannell
  • 通讯作者:
    Lewis K. Pannell
A new class of alkaloids from a dendrobatid poison frog: a structure for alkaloid 251F.
来自 dendrobatid 毒蛙的一类新生物碱:生物碱 251F 的结构。
  • DOI:
    10.1021/np50084a002
  • 发表时间:
    1992
  • 期刊:
  • 影响因子:
    5.1
  • 作者:
    T. Spande;H. Garraffo;H. Yeh;Q.;Lewis K. Pannell;John W. Daly
  • 通讯作者:
    John W. Daly
Rectal Effluent as a Research Tool
  • DOI:
    10.1007/s10620-014-3330-0
  • 发表时间:
    2014-09-02
  • 期刊:
  • 影响因子:
    2.500
  • 作者:
    Jana M. Rocker;Jack A. DiPalma;Lewis K. Pannell
  • 通讯作者:
    Lewis K. Pannell
Primary structure of a novel neuropeptide isolated from the corpora cardiaca of periodical cicadas having adipokinetic and hypertrehalosemic activities.
从具有脂肪运动和高海藻糖活性的周期蝉贲门体中分离出的新型神经肽的一级结构。
Transition metal complexes of 3-acetylisoquinoline thiosemicarbazones as potential antifungal agents
  • DOI:
    10.1007/bf02910711
  • 发表时间:
    1992-10-01
  • 期刊:
  • 影响因子:
    1.700
  • 作者:
    John P. Scovill;Michael W. Blaney;Douglas X. West;Anthony E. Liberta;Lewis K. Pannell
  • 通讯作者:
    Lewis K. Pannell

Lewis K. Pannell的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Lewis K. Pannell', 18)}}的其他基金

A Novel Approach for the Routine Screening for Ovarian Cancer
卵巢癌常规筛查的新方法
  • 批准号:
    8551644
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Profiling Urine Glycosylation of PSA and other Glyco-Biomarkers in Prostate Cance
分析前列腺癌中 PSA 和其他糖生物标志物的尿液糖基化
  • 批准号:
    7386271
  • 财政年份:
    2008
  • 资助金额:
    --
  • 项目类别:
Profiling Urine Glycosylation of PSA and other Glyco-Biomarkers in Prostate Cance
前列腺癌中 PSA 和其他糖生物标志物的尿液糖基化分析
  • 批准号:
    7576898
  • 财政年份:
    2008
  • 资助金额:
    --
  • 项目类别:
Automated Glyco-Analysis of Cancer Related Proteins
癌症相关蛋白的自动糖分析
  • 批准号:
    7140158
  • 财政年份:
    2005
  • 资助金额:
    --
  • 项目类别:
Automated Glyco-Analysis of Cancer Related Proteins
癌症相关蛋白质的自动糖分析
  • 批准号:
    6961743
  • 财政年份:
    2005
  • 资助金额:
    --
  • 项目类别:
MASS SPECTROMETRY OF DRUGS, NATURAL PRODUCTS, PROTEINS, AND OLIGONUCLEOTIDES
药物、天然产物、蛋白质和寡核苷酸的质谱分析
  • 批准号:
    6105233
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Mass Spectrometry Of Drugs, Natural Products, Proteins,
药物、天然产物、蛋白质的质谱分析,
  • 批准号:
    6507291
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
MASS SPECTROMETRY OF DRUGS, NATURAL PRODUCTS, PROTEINS, AND OLIGONUCLEOTIDES
药物、天然产物、蛋白质和寡核苷酸的质谱分析
  • 批准号:
    6432107
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Mass Spectrometry Of Drugs, Natural Products, Proteins,
药物、天然产物、蛋白质的质谱分析,
  • 批准号:
    6673454
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了